GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

Original reporting
Published Nov 18, 2026, 10:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GSK gets second cancer drug approval from Nuvalent buy — source image
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

This is a direct regulatory milestone that can change commercial expectations for GSK’s oncology segment and validate the Nuvalent pipeline strategy, while leaving pricing and confirmatory evidence as key uncertainties.

02

Market read

Traders can reassess GSK’s oncology growth trajectory as a second Nuvalent-derived drug gains FDA clearance, supported by ALKOVE-1 response and durability data.

03

What to watch

The article notes GSK has not yet revealed US list price, and the competitive ALKAZAR head-to-head versus Alecensa could shift uptake expectations.

Relevance 7/10Novelty 8/10Timing: FDA clearance reported today, with US launch implications.

Background

GSK acquired Nuvalent earlier this year and is now receiving FDA clearances for multiple targeted NSCLC drugs, including ROS1 inhibitor Jideytro and now ALK inhibitor Nelkarmi.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

FDA cleared GSK’s ALK inhibitor Nelkarmi for advanced ALK-positive NSCLC, the second oncology product from its Nuvalent acquisition.

Expected impact

Likely positive bias as investors price in incremental oncology revenue and validate the Nuvalent pipeline execution.

Evidence & confidence

The article reports a fresh FDA clearance for Nelkarmi, includes trial efficacy metrics, and frames it as a second Nuvalent-derived oncology product, which is directly tradable for a biotech/pharma holder.

Market effects

Reinforces competitive momentum in ALK/ROS1 NSCLC targeted therapies and supports the broader oncology pipeline narrative for large pharma post-acquisition.

Primarily US regulatory-driven, but can influence European pharma sentiment given GSK’s UK base.

Could affect global ALK/ROS1 treatment sequencing expectations and competitive positioning across major markets.

Counterpoint

Accelerated approvals can face future confirmatory-trial risk, so near-term enthusiasm may over-discount durability and label expansion outcomes.

Key entities

  • GSK

    Sponsor of Nelkarmi (neladalkib) and acquirer of Nuvalent, receiving FDA clearance for an ALK-positive NSCLC indication.

  • Nuvalent

    Biotech acquired by GSK earlier this year; its pipeline is now producing FDA-cleared oncology products.

  • FDA

    Cleared Nelkarmi for advanced ALK-positive NSCLC under an accelerated approval pathway.

Related articles

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.

$GSKHigh

GSK Wins Early FDA Nod for Nelkarmi

GSK (LON: GSK) received accelerated FDA approval for its lung cancer drug Nelkarmi (neladalkib) for ALK-positive non-small cell lung cancer. The approval, based on early trial data, came before the November 27 target date. GSK shares were down 0.16% at 1866p. The drug showed a 49% response rate in patients previously treated with alectinib. GSK also plans to acquire Nuvalent for $10.6bn.

$GSKMed

FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung Cancer

The FDA granted accelerated approval to GSK’s neladalkib (Nelkarmi) for adults with previously treated ALK-positive metastatic or locally advanced NSCLC. Based on the Phase I/II ALKOVE-1 trial, confirmed ORR was 49% (after alectinib) and 32% (after multiple ALK TKIs plus platinum), with intracranial ORR 55% and 26%. Key safety issues included hepatotoxicity (56%).